S&P 500   4,574.19 (+0.14%)
DOW   36,042.72 (+0.26%)
QQQ   387.75 (-0.28%)
AAPL   190.63 (+0.36%)
MSFT   372.49 (-1.69%)
META   321.82 (-1.63%)
GOOGL   130.90 (-1.23%)
AMZN   146.18 (+0.06%)
TSLA   236.47 (-1.50%)
NVDA   466.29 (-0.30%)
NIO   7.11 (-2.20%)
BABA   72.83 (-2.74%)
AMD   120.24 (-0.76%)
T   16.66 (+0.54%)
F   10.45 (+1.85%)
MU   76.19 (+0.09%)
CGC   0.58 (+3.13%)
GE   122.73 (+0.76%)
DIS   91.99 (-0.76%)
AMC   6.77 (+1.80%)
PFE   29.13 (-4.40%)
PYPL   58.17 (+0.97%)
XOM   103.75 (+0.98%)
S&P 500   4,574.19 (+0.14%)
DOW   36,042.72 (+0.26%)
QQQ   387.75 (-0.28%)
AAPL   190.63 (+0.36%)
MSFT   372.49 (-1.69%)
META   321.82 (-1.63%)
GOOGL   130.90 (-1.23%)
AMZN   146.18 (+0.06%)
TSLA   236.47 (-1.50%)
NVDA   466.29 (-0.30%)
NIO   7.11 (-2.20%)
BABA   72.83 (-2.74%)
AMD   120.24 (-0.76%)
T   16.66 (+0.54%)
F   10.45 (+1.85%)
MU   76.19 (+0.09%)
CGC   0.58 (+3.13%)
GE   122.73 (+0.76%)
DIS   91.99 (-0.76%)
AMC   6.77 (+1.80%)
PFE   29.13 (-4.40%)
PYPL   58.17 (+0.97%)
XOM   103.75 (+0.98%)
S&P 500   4,574.19 (+0.14%)
DOW   36,042.72 (+0.26%)
QQQ   387.75 (-0.28%)
AAPL   190.63 (+0.36%)
MSFT   372.49 (-1.69%)
META   321.82 (-1.63%)
GOOGL   130.90 (-1.23%)
AMZN   146.18 (+0.06%)
TSLA   236.47 (-1.50%)
NVDA   466.29 (-0.30%)
NIO   7.11 (-2.20%)
BABA   72.83 (-2.74%)
AMD   120.24 (-0.76%)
T   16.66 (+0.54%)
F   10.45 (+1.85%)
MU   76.19 (+0.09%)
CGC   0.58 (+3.13%)
GE   122.73 (+0.76%)
DIS   91.99 (-0.76%)
AMC   6.77 (+1.80%)
PFE   29.13 (-4.40%)
PYPL   58.17 (+0.97%)
XOM   103.75 (+0.98%)
S&P 500   4,574.19 (+0.14%)
DOW   36,042.72 (+0.26%)
QQQ   387.75 (-0.28%)
AAPL   190.63 (+0.36%)
MSFT   372.49 (-1.69%)
META   321.82 (-1.63%)
GOOGL   130.90 (-1.23%)
AMZN   146.18 (+0.06%)
TSLA   236.47 (-1.50%)
NVDA   466.29 (-0.30%)
NIO   7.11 (-2.20%)
BABA   72.83 (-2.74%)
AMD   120.24 (-0.76%)
T   16.66 (+0.54%)
F   10.45 (+1.85%)
MU   76.19 (+0.09%)
CGC   0.58 (+3.13%)
GE   122.73 (+0.76%)
DIS   91.99 (-0.76%)
AMC   6.77 (+1.80%)
PFE   29.13 (-4.40%)
PYPL   58.17 (+0.97%)
XOM   103.75 (+0.98%)

ARK Genomic Revolution ETF (ARKG) Price, Holdings, & News

$27.74
-0.38 (-1.35%)
(As of 11/30/2023 ET)
Compare
Today's Range
$27.60
▼
$28.65
50-Day Range
$22.22
▼
$28.19
52-Week Range
N/A
Volume
3.81 million shs
Average Volume
N/A
Market Capitalization
$1.81 billion
Assets Under Management
$1.76 billion
Dividend Yield
N/A
Net Expense Ratio
0.75%
Stock AnalysisChartHeadlinesHoldingsOwnershipRatings
ARKG stock logo

About ARK Genomic Revolution ETF (BATS:ARKG)

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.

ARKG Stock Price History

ARKG ETF News Headlines

November 28, 2023 | za.investing.com
ARK boosted its stake in this TechBio company by 45% on Monday
October 24, 2023 | msn.com
Moderna’s stock snaps record losing streak as Cathie Wood’s ETF boosts stake by more than $4 million
December 1, 2023 | DTI Trader (Ad)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
October 2, 2023 | msn.com
Cathie Wood's Ark Invest Sells Nearly $4M Worth Of NVIDIA Shares — Does It Herald Shift To Undervalued AI Gems?
September 12, 2023 | markets.businessinsider.com
Cathie Wood's Ark Invest Bumps Up Stake In This Chipmaker After Selling $10M Worth Of Nvidia Last Week
August 25, 2023 | benzinga.com
Cathie Wood's Ark Invest Adjusts Portfolio — Sells Nvidia Shares Worth Nearly $1.9M Amid AI Surge
August 23, 2023 | finance.yahoo.com
‘Thematic Fatigue’ Hobbles Once-Hot Slice of ETFs With Outflows
July 11, 2023 | forbes.com
Elon Musk, Steve Wozniak Sound Alarm On Dangerous AI
December 1, 2023 | DTI Trader (Ad)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
July 2, 2023 | msn.com
ARKG: Outperforming XBI, Reasonably Valued With Technical Upside Potential In 2H
See More Headlines
Receive ARKG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARK Genomic Revolution ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
ARK
Fund Name
ARK Genomic Revolution ETF
Tax Classification
Regulated Investment Company
Stock Exchange
BATS
Current Symbol
BATS:ARKG
Inception Date
10/31/2014
Fund Manager
Catherine Wood
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
N/A
Category
Strategy
Focus
Theme
Development Level
Blended Development
Region
Global
Number of Holdings
42

Fund Statistics

Assets Under Management
$1.79 billion
Average Daily Volume
$3.12 million
Discount/Premium
-0.02%

Administrator, Advisor and Custodian

Administrator
The Bank of NewYork Mellon Corporation
Advisor
ARK Investment Management LLC
Custodian
The Bank of NewYork Mellon Corporation
Distributor
Foreside Fund Services, LLC
Transfer Agent
The Bank of NewYork Mellon Corporation
Trustee
N/A
Lead Market Maker
Jane Street

Options

Optionable
Optionable
Options Volume
6,463
Put Options
1,890
Call Options
4,573

Miscellaneous

Outstanding Shares
65,100,000
Beta
1.50
Creation Unit
50,000
Creation Fee
$500.00
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

ARK Genomic Revolution ETF Expenses

TypeARKGTheme ETFsEquity ETFsBATS ETFsAll ETFs
Management Fee0.75%0.57%0.53%0.55%0.51%
Other Expenses0.00%0.76%0.53%0.51%0.57%
Total Expense0.75%0.73%0.69%0.68%0.69%
Fee Waiver0.00%-0.78%-0.54%-0.36%-0.58%
Net Expense0.75%0.60%0.59%0.62%0.57%

ARK Genomic Revolution ETF (ARKG) Holdings & Exposure

Top 10 ARKG Holdings

ARKG Sector Exposure

ARKG Industry Exposure

Full Holdings Details














ARKG ETF - Frequently Asked Questions

How have ARKG shares performed in 2023?

ARK Genomic Revolution ETF's stock was trading at $28.23 on January 1st, 2023. Since then, ARKG shares have decreased by 1.7% and is now trading at $27.74.
View the best growth stocks for 2023 here.

What does ARKG invest in?

ARK Genomic Revolution ETF is a equity fund issued by ARK. ARKG focuses on theme investments. The fund's investments total to approximately $1.79 billion assets under management.

What stocks does ARK Genomic Revolution ETF hold?

ARKG invests in 42 holdings. Some of the stocks in their portfolio include Exact Sciences (EXAS), Schrödinger (SDGR), Pacific Biosciences of California (PACB), Teladoc Health (TDOC), Ginkgo Bioworks (DNA), Ionis Pharmaceuticals (IONS), Adaptive Biotechnologies (ADPT), Accolade (ACCD), CRISPR Therapeutics (CRSP) and CareDx (CDNA).

What is the management fee for ARK Genomic Revolution ETF?

ARK Genomic Revolution ETF's management fee is 0.75% and has no other recorded expenses or fee waivers. The net expense ratio for ARKG is 0.75%.

Who are ARK Genomic Revolution ETF's major shareholders?

ARK Genomic Revolution ETF's stock is owned by many different retail and institutional investors. Top institutional shareholders include Morgan Stanley (4.93%), LPL Financial LLC (1.42%), Citigroup Inc. (0.99%), UBS Group AG (0.76%), Commonwealth Equity Services LLC (0.67%) and Affinity Asset Advisors LLC (0.00%).

How do I buy shares of ARK Genomic Revolution ETF?

Shares of ARKG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (BATS:ARKG) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -